In a second trial, autologous mature VitD3-tolDCs loaded with proinsulin peptide C19-A3 were intradermally administered twice in T1D patients (clinicaltrials.gov identifier: NCT04590872). The gene discussed is INS; the disease is type 1 diabetes mellitus.